Dr. Usmani On Mechanisms And Response Rates With Daratumumab In Myeloma

Dr. Usmani on Mechanisms and Response Rates With Daratumumab in Myeloma

Dr. Usmani on Subcutaneous Delivery of Daratumumab in Myeloma

Dr. Usmani on Minimal Residual Disease in Multiple Myeloma

Dr. Usmani on Combining Daratumumab for Multiple Myeloma

Mechanism of action of daratumumab

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Saad Usmani on Daratumumab Monotherapy for Multiple Myeloma

M-Power NY | Dr. Saad Usmani Presents Myeloma Treatments: How Do We Treat Myeloma?

International Myeloma Foundation

Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma

Dr. Usmani on Importance of CASTOR/POLLUX Trials in Myeloma

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

American Society of Hematology

Dr. Saad Usmani Discusses Advances in Multiple Myeloma (MM)

J&J Innovative Medicine

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

The role of daratumumab in the treatment of myeloma and insights into the MAIA trial

VJHemOnc – Video Journal of Hematology & HemOnc

ASCO 2019: Daratumumab and the MAIA Trial with Dr. Saad Usmani

HealthTree Foundation for Multiple Myeloma

Dr. Usmani on Situations that Indicate the Need for Immediate Treatment in R/R Multiple Myeloma

Does using daratumumab make response-monitoring difficult?

International Myeloma Foundation

Dr. Usmani on Treatment of Newly Diagnosed Myeloma

Saad Usmani: Adding Daratumumab to Carfilzomib + Dexamethasone Extends PFS

American Society of Hematology

Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma

Dr. Usmani Discusses Management of Early Relapse in Myeloma